Pharmacogenetic Data With Clinical Outcomes Should Be Described In Label

Pharmacogenetic variations with demonstrated clinical outcomes should be discussed in drug labeling, members of FDA's Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science said at its April 23 meeting